All Drug Discovery Processes articles – Page 2
-
ArticleAnticipating adaptation: understanding and overcoming cancer drug resistance
Neil Bhowmick explores how understanding the mechanisms of cancer drug resistance has reframed our approach to treatment, revealing containment and control as realistic goals for therapeutic strategies.
-
ArticleKMA and LMA antigens emerge as high value targets for plasma cell dyscrasia treatment
Research published in Clinical Lymphoma, Myeloma and Leukemia identifies Kappa Myeloma Antigen and Lambda Myeloma Antigen as highly selective immunotherapy targets across plasma cell dyscrasias.
-
NewsCOPD drug roflumilast may help fight breast cancer lung metastasis
University of Colorado Anschutz Cancer Center scientists have uncovered how metastatic breast cancer cells exploit pulmonary repair pathways to establish tumours in the lungs.
-
NewsNew evidence links autoantibodies to Long COVID
Dutch researchers have demonstrated that IgG autoantibodies from Long COVID patients can induce persistent pain-like hypersensitivity in mice, with effects lasting at least two weeks. The study identifies distinct biological subgroups and suggests that autoimmune mechanisms may drive the condition’s diverse symptomatology, opening avenues for targeted immunotherapies.
-
NewsCD47 protein found to drive glioblastoma growth
University of Adelaide researchers have discovered that CD47, a protein known for helping cancer cells evade immune detection, also directly promotes glioblastoma growth and invasion through a novel molecular pathway involving ROBO2 stabilisation.
-
NewsToxoplasma cell cycle mapped for next-generation therapies
University of South Florida researchers have adapted fluorescent imaging to visualise the cell cycle of Toxoplasma gondii in real time, revealing an unusual branching growth pattern that enables rapid multiplication. The breakthrough could identify new therapeutic targets for toxoplasmosis, which affects one-third of the global population and has limited treatment options once chronic.
-
NewsBlocking protein pathway may slow Huntington’s disease
Researchers have identified a previously unknown cellular mechanism involving tunnelling nanotubes and the protein SLC4A7 that enables toxic huntingtin to spread directly between neurons, offering new therapeutic targets for Huntington’s disease.
-
NewsBiomarker discovery may improve schizophrenia treatment
Northwestern University scientists have identified a circulating brain protein biomarker that is significantly reduced in schizophrenia patients and developed a synthetic therapeutic that corrected abnormal brain activity in preclinical models, offering hope for treating the disorder’s debilitating cognitive symptoms.
-
NewsGut microbes found to drive chronic kidney disease
A newly discovered feedback loop between impaired kidney function and gut bacteria may drive disease progression through toxic compound production. UC Davis researchers have identified a potential therapeutic target to interrupt this damaging cycle.
-
WebinarWhat it takes to automate high-content imaging at scale
This webinar examines the design trade-offs and technical constraints involved in building a high-throughput robotic imaging pipeline for complex biological workflows.
-
InterviewFrom scientist to bioinformatician: how AI coding tools dissolved the activation energy barrier
A biotech CEO with decades of scientific experience but sporadic coding practice gained practical bioinformatics capabilities in six weeks using AI coding assistants.
-
NewsNew AI-designed T-cell engager LGTX-101 to be presented at AACR in San Diego
LabGenius Therapeutics will present preclinical data for LGTX-101, its AI-designed Nectin-4 x CD3 T-cell engager, at AACR 2026 in San Diego.
-
NewsProbiotic bacteria successfully attacks tumours in preclinical models
Engineered probiotic bacteria that can deliver cancer-fighting drugs directly to tumours have shown promising results in mice, offering a potential new approach to targeted cancer therapy.
-
NewsSonoPIN ultrasound method shows promise for targeted cancer therapy
A new ultrasound-based technique developed by researchers at Duke University uses microbubbles to deliver cancer drugs directly into tumour cells, showing promise for highly targeted treatments that cause minimal damage to healthy tissue.
-
NewsELRIG announces keynote speakers for Advances in Cell-based Screening 2026 in Gothenburg
ELRIG has announced the keynote speakers for its 2026 Advances in Cell-based Screening conference in Gothenburg, where scientists will gather to explore how human-first models, advanced cell biology and AI are changing the future of drug discovery.
-
ArticleWhy NMDA receptor modulation remains central to next-generation depression therapies
A key player in brain communication and mood regulation, the pharmaceutical industry views the NMDAR as the central pillar for next-generation therapies for depression. Dirk Beher from FundaMental Pharma reveals new strategies for targeting this important receptor.
-
NewsNew RNA injection could help hearts heal after heart attacks
A new RNA-based therapy developed at Columbia University could help the heart repair itself after a heart attack without invasive surgery.
-
ArticleDesigning targeted assays for clinical success from the start
Why do some targeted assays move smoothly from discovery to clinical practice while others stall? The answer often lies in the earliest design decisions, where choices about samples, platforms and data determine what is possible later.
-
NewsLight-driven chemistry offers faster, greener drug design
Scientists at the University of Cambridge have developed a light-powered method to modify complex drug molecules without toxic chemicals, enabling faster, cleaner and more efficient drug development.
-
NewsScientists develop cream that triggers skin’s anti-cancer defence
A topical cream that activates the skin’s immune defences has been shown to suppress tumour growth in early models of cutaneous squamous cell carcinoma.